Fulltext

An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors

Nwanaji-Enwerem JC 1 , Chung FF 2 , Van der Laan L 3 , Novoloaca A 2 , Cuenin C 2 , Johansson H 4 Show all authors , Bonanni B 4 , Hubbard AE 3 , Smith MT 3 , Hartman SJ 5 , Cardenas A 3 , Sears DD 6 , Herceg Z 2

Affiliations 

  • 1 Department of Emergency Medicine, Gangarosa Department of Environmental Health, Emory University School of Medicine, Emory Rollins School of Public Health, 1518 Clifton Rd. NE, Atlanta, GA, 30322, USA. jnwanaj@emory.edu
  • 2 Epigenomics and Mechanisms Branch, International Agency for Research on Cancer, Lyon, France
  • 3 Division of Environmental Health Sciences, School of Public Health and Center for Computational Biology, University of California, Berkeley, Berkeley, CA, USA
  • 4 Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435 - 20141, Milan, Italy
  • 5 Herbert Wertheim School of Public Health, University of California, San Diego, CA, USA
  • 6 College of Health Solutions, Arizona State University, Phoenix, AZ, USA
Clin Epigenetics, 2021 12 17;13(1):224.
PMID: 34920739 DOI: 10.1186/s13148-021-01218-y

Abstract

Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied. We performed a post-hoc analysis of a randomized controlled trial among overweight/obese breast cancer survivors (N = 192) assigned to metformin, placebo, weight loss with metformin, or weight loss with placebo interventions for 6 months. Epigenetic age was correlated with chronological age (r = 0.20-0.86; P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications